BMC Research Notes | |
Clinical, immunological, and virological outcomes of pediatric antiretroviral therapy in central China | |
Dongchi Zhao1  Junwen Zheng1  | |
[1]Department of Pediatrics, Zhongnan Hospital of Wuhan University, Wuhan 430071, China | |
关键词: Infectious diseases outcomes; Antiretroviral therapy; Pediatrics; Medical practice; HIV/AIDS; | |
Others : 826322 DOI : 10.1186/1756-0500-7-419 |
|
received in 2009-02-26, accepted in 2014-06-30, 发布年份 2014 | |
【 摘 要 】
Background
Antiretroviral therapy (ART) reduces HIV-related mortality and morbidity substantially in children. The clinical characteristics, immunological and virological outcomes were evaluated in HIV-infected children receiving ART.
Methods
Twenty-six HIV-1-infected children receiving ART in Hubei province, China, were enrolled retrospectively in this study. During the period of ART, plasma viral load, lymphocyte phenotype of CD4 and CD8 cells and clinical events were assessed.
Results
The median duration of ART was 41 months (18–72.3 months). In children showing clinical improvement, high viral suppression rate below log10 (2.7) copies/ml by the third months of ART was observed. The median CD4 cell counts reached to 820.5/μl by 12 months and the median ratio of CD4/CD8 increased to 0.6 by 21 months. The counts of peripheral white blood cells and red blood cells decreased in the first 12 months, while Hb concentration, MCV and MCH increased (P < 0.001).
Conclusions
Despite the limited small sample size, ART is an effective strategy for inhibiting HIV replication and reconstructing the immunological response in children with AIDS.
【 授权许可】
2014 Zheng and Zhao; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20140713093338805.pdf | 410KB | download | |
Figure 4. | 32KB | Image | download |
Figure 3. | 40KB | Image | download |
Figure 2. | 46KB | Image | download |
Figure 1. | 51KB | Image | download |
【 图 表 】
Figure 1.
Figure 2.
Figure 3.
Figure 4.
【 参考文献 】
- [1]World Health Organization: Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1 webcite
- [2]Sutcliffe C, Dijk J, Bolton C, Persaud D, Moss W: Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008, 8:477-489.
- [3]Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sönnerborg A: Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002, 16:1039-1044.
- [4]The European Collaborative Study: Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics 2003, 111:52-60.
- [5]Guillén S, Ramos J, Resino R, Bellón J, Muñoz M: Impact on Weight and Height With the Use of HAART in HIV-Infected Children. Pediatr Infect Dis J. 2007, 26:334-338.
- [6]Zhao Y, Li C, Sun X, Mu W, McGoogan JM, He Y, Cheng Y, Tang Z, Li H, Ni M, Ma Y, Chen R, Liu Z, Zhang F: Mortality and Treatment Outcomes of China's National Pediatric Antiretroviral Therapy Program. Clin Infect Dis 2013, 56:735-744.
- [7]Zhang FJ, Haberer J, Zhao Y, Dou Z, Zhao H, He Y, Cao GH: Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes. AIDS 2007, 21(suppl 8):143-S148.
- [8]O’Brien D, Sauvageot D, Zachariah R, Humblet P: In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006, 20:1955-1960.
- [9]World Health Organization (WHO): Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for a public health approach. Available at:/http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf webcite
- [10]Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie J, Guerin P, Brasher C: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006, 367:1335-1342.
- [11]Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui K, Timite M, Blanche S, Msellati P: Highly active antiretroviral therapies among HIV-1–infected children in Abidjan, Cote d’Ivoire. AIDS 2004, 18:1905-1913.
- [12]O'Brien D, Sauvageot D, Olson D, Schaeffer M, Humblet P, Pudjades M, Ellman T, Zachariah R, Szumilin E, Arnould L, Read T, Médecins Sans Frontières: Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin Infect Dis 2007, 44:1245-1248.
- [13]Mulu A, Liebert UG, Maier M: Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. BMC Infect Dis 2014, 14:28. BioMed Central Full Text
- [14]Ananworanich J, Kosalaraksa P, Siangphoe U, Engchanil C, Pancharoen C, Lumbiganon P, Intasan J, Apateerapong W, Chuenyam T, Ubolyam S, Bunupuradah T, Lange J, Cooper D, Phanuphak P, the HIV-NAT 010 Study Team: A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection. AIDS Res Ther 2008, 5:24. BioMed Central Full Text
- [15]Bolton-Moore C, Mubiana-Mbewe M, Cantrell R, Chintu N, Stringer E, Chi B, Sinkala M, Kankasa C, Wilson C, Wilfert C, Mwango A, Levy J, Abrams E, Bulterys M, Stringer J: Clinical Outcomes and CD4 Cell Response in Children Receiving Antiretroviral Therapy at Primary Health Care Facilities in Zambia. JAMA 2007, 298:1888-1899.
- [16]Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Watcharananan S, Sathapatayavongs B: Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting. AIDS Res Ther 2007, 4:26. BioMed Central Full Text
- [17]Soh C, Oleske J, Brady M, Spector S, Borkowsky W, Burchett S, Foca M, Handelsman E, Jiménez E, Dankner W, Pediatric HM, AIDS: Clinical Trials Group. Long-term effects of proteaseinhibitor–based combination therapy on CD4 T-cell recovery in HIV-1–infected children and adolescents. Lancet 2003, 362:2045-2051.
- [18]Griensven J, Naeyer L, Uwera J, Asiimwe A, Gazille C, Reid T: Success with antiretroviral treatment for children in Kigali, Rwanda: Experience with health center/nurse-based care. BMC Pediatr 2008, 8:39. BioMed Central Full Text
- [19]Gonzalez-Tome M, Amador J, Peña M, Gomez M, Conejo P, Fontelos P: Outcome of protease inhibitor substitution with nevirapine IN HIV-1 infected children. BMC Infect Dis 2008, 8:144. BioMed Central Full Text
- [20]Dreimane D, Nielsen K, Deveikis A, Bryson Y, Gegrz R: Effects of protease inhibitors combine with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2001, 20:315-316.
- [21]Pornprasert S, Leechanachai P, Klinbuayaem V, Leenasirimakul P, Sukunthamala K, Thunjai B, Phusua A, Saetung R, Sanguansermsri T: Effect of haematological alterations on thalassaemia investigation in HIV-1-infected Thai patients receiving antiretroviral therapy. HIV Med 2008, 9:660-666.
- [22]Eyer-Silva W, Arabe J, Pinto J, Morais-De-Sá C: Macrocytosis in patientson stavudine. Scand J Infect Dis 2001, 33:239-240.
- [23]Routy J, Monte M, Beaulieu R, Toma E, St-Pierre L, Dumont M: Increaseof hemoglobin A2 in human immunodeficiency virus-1-infected patients treated with zidovudine. Am J Hematol 1993, 43:86-90.